4.7 Article

Antimicrobial Activity of Solithromycin against Serotyped Macrolide-Resistant Streptococcus pneumoniae Isolates Collected from US Medical Centers in 2012

Journal

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 59, Issue 4, Pages 2432-2434

Publisher

AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.04568-14

Keywords

-

Funding

  1. CEMPRA Pharmaceuticals (Chapel Hill, NC)

Ask authors/readers for more resources

Solithromycin, a next-generation macrolide and novel fluoroketolide, was tested against a 2012 collection of serotyped U.S. macrolide-resistant Streptococcus pneumoniae isolates associated with community-acquired bacterial pneumonia (CABP). Against all 272 isolates, solithromycin demonstrated high potency (MIC50/90, 0.06/0.25 mu g/ml), and it inhibited all strains at MICs of <= 0.5 mu g/ml, including the two most prevalent macrolide-resistant serotypes (19A and 35B). These data support the continued clinical development of solithromycin for the treatment of multidrug-resistant CABP.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available